Company Overview - DURECT Corporation is a late-stage biopharmaceutical company focused on developing epigenetic therapies targeting dysregulated DNA methylation to treat serious conditions, including acute organ injury [3] - The lead drug candidate, larsucosterol, inhibits DNA methyltransferases associated with hypermethylation in acute hepatitis (AH) patients and is in clinical development [3] Financial Results Announcement - DURECT Corporation will report its fourth quarter and full year 2024 financial results on March 26, 2025, followed by a conference call and webcast at 4:30 pm Eastern Time [1][2] Drug Development and Designations - Larsucosterol has received Fast Track and Breakthrough Therapy designations from the FDA for the treatment of AH, indicating its potential significance in addressing this condition [3] - The company is also exploring larsucosterol for other indications, including MASH [3] Additional Product Information - POSIMIR® (bupivacaine solution) is FDA-approved for infiltration use and utilizes the SABER® platform technology, representing another product in DURECT's portfolio [3]
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update